Active — Not RecruitingPhase 2/3

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

United States1,000 participantsStarted 2019-04-04

Plain-language summary

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Have completed 24 weeks of treatment in a previous qualifying CTP-543 clinical trial Exclusion Criteria: * Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or untreated actinic keratosis * Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study medication * Donation of blood at any point throughout the study and for 30 days after last dose of study medication

What they're measuring

Number of Participants with Adverse Events as a Measure of Safety

Timeframe: 332 weeks

Effect of CTP-543 on treating hair loss as measured by the Severity of Alopecia Tool (SALT)

Timeframe: 332 weeks

Trial details

NCT IDNCT03898479

SponsorSun Pharmaceutical Industries, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2027-05

View on ClinicalTrials.gov More Alopecia Areata trials